---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123274"
form_type: "8-K"
ticker: "BOLD"
cik: "0001782303"
company_name: "Boundless Bio, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:42:50.445198+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Boundless Bio Q3 net loss $16.5M; cash $167.1M, runway into Q4 2026

## Summary
- Net loss of $16.5M for Q3 2024 vs $13.2M in Q3 2023; R&D expenses $14.1M.
- Cash, cash equivalents, and short-term investments total $167.1M as of Sept 30, 2024.
- Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP trials; initial proof-of-concept data expected H2 2025.
- Analytical validation for proprietary ecDNA diagnostic ECHO presented at ESMO September 2024.
- G&A expenses $4.6M vs $3.3M year-over-year; general operating cash runway into Q4 2026.

## SEC filing metadata
- accession: 0000950170-24-123274
- form_type: 8-K
- ticker: BOLD
- cik: 0001782303
- company_name: Boundless Bio, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782303/000095017024123274/0000950170-24-123274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782303/000095017024123274/bold-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123274
- JSON: https://secwatch.observer/filing/0000950170-24-123274.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123274.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.